Ubs Group Ag Pharvaris N.V. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Pharvaris N.V. stock. As of the latest transaction made, Ubs Group Ag holds 7,449 shares of PHVS stock, worth $122,834. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,449

Previous 1,045 612.82%

Holding current value

$122,834

Previous $20,000 480.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$14.9 - $19.54 $95,419 - $125,134	6,404 Added 612.82%	7,449 $116,000
Q4 2024 Feb 14, 2025	SELL	$17.87 - $25.01 $9,757 - $13,655	-546 Reduced 34.32%	1,045 $20,000
Q3 2024 Nov 14, 2024	BUY	$15.73 - $21.4 $22,399 - $30,473	1,424 Added 852.69%	1,591 $29,000
Q2 2024 Aug 13, 2024	BUY	$15.67 - $24.59 $2,616 - $4,106	167 New	167 $3,000
Q3 2023 Nov 09, 2023	SELL	$14.68 - $21.4 $18,350 - $26,750	-1,250 Reduced 96.15%	50 $1,000
Q2 2023 Aug 11, 2023	BUY	$7.82 - $16.0 $6,865 - $14,048	878 Added 208.06%	1,300 $19,000
Q1 2023 May 12, 2023	SELL	$6.34 - $12.27 $15,076 - $29,178	-2,378 Reduced 84.93%	422 $3,000
Q4 2022 Feb 08, 2023	BUY	$1.98 - $11.46 $5,544 - $32,088	2,800 New	2,800 $31,000
Q2 2022 Aug 10, 2022	BUY	$16.35 - $27.5 $1,160 - $1,952	71 Added 9.75%	799 $18,000
Q1 2022 May 16, 2022	BUY	$15.98 - $19.65 $4,873 - $5,993	305 Added 72.1%	728 $13,000
Q4 2021 Feb 14, 2022	SELL	$13.28 - $18.0 $3,067 - $4,158	-231 Reduced 35.32%	423 $6,000
Q3 2021 Nov 15, 2021	BUY	$13.14 - $20.97 $8,593 - $13,714	654 New	654 $12,000
Q2 2021 Aug 13, 2021	SELL	$18.05 - $29.59 $577 - $946	-32 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$25.25 - $40.11 $808 - $1,283	32 New	32 $1,000

Others Institutions Holding PHVS

# of Institutions

Shares Held

39.1M

Call Options Held

Put Options Held

View Full List

About Pharvaris N.V.

Ticker PHVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,766,000
Market Cap $557M
Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...

More about PHVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account